美罗华联合CHOP方案与CHOP方案治疗老年复发性弥漫性大B细胞性淋巴瘤的临床研究

Comparison of Rituximab plus CHOP Regimen and CHOP Regimen Alone for Treatment of old Patients with Recurrence Aggressive B-cell Lymphoma

目的:探讨美罗华联合CHOP方案与CHOP方案治疗老年复发性弥漫性大B细胞性淋巴瘤的临床疗效和不良反应。方法:选择老年复发性弥漫性大B细胞性淋巴瘤60例,按治疗方案分成研究组(30例)和对照组(n=30),研究组采用美罗华联合CHOP方案,对照组给予单纯CHOP方案。评估比较两组患者疗效和不良反应,并随访两组患者的生存时间。结果:两组患者均完成治疗及治疗效果评估,研究组CR为10例,PR为15例,总有效率为83.3%(25/30);对照组CR为3例,PR为6例,总有效率为30.0%(9/30),研究组有效率明显高于对照组(X2=8.42,P<0.05)。随访期间,研究组MST、PFS明显长于对照组(P<0.05)。研究组和对照组1年生存率、2年生存率比较,差异有统计学意义(P<0.01)。两组间抗癌药物毒性分度比较,差异无统计学意义(P>0.05)。结论:美罗华联合CHOP方案用于老年复发性弥漫性大B细胞淋巴瘤,能明显提高治疗有效率,延长无进展生存期和生存时间,且没有增加老年患者毒副作用,应用安全。

Objective： To investigate the efficacy and security of old patients with recurrence aggressive B-cell lymphoma treaded by Rituximab plus CHOP regimen and CHOP regimen alone. Methods： Sixty old patients with recurrence aggressive B- cell lymphoma were randomly divided into test group （n=30）and control group （n=30）. The patients received the treatment of Rituximab plus CHOP regimen in test group, and the treatment of CHOP regimen alone in control group. The effect, adverse events and survival time in two groups were observed and compared. Results： In test group, total response rate was 83.3% （25/30）, while in control group 30.0% （9/30）. The total response rate in test group were remarkably higher than that in control group （X2-=-8.42, P〈0.01）. The median survival time and PFS in test group were longer than that of conrol group（P〈0.01）. The survival rate in 1 year and 2 years of test group was higher than that of control（P〈0.01）. There was no significant difference on adverse events between the two groups（P〉0.05）. Conclusion： Rituximab plus CHOP regimen for old patients with recurrence aggressive B-cell lymphoma can increase the response rate and prolongs PFS and median survival time with low adverse events.